Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03689114
Other study ID # STANDLOW
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date May 10, 2021
Est. completion date August 31, 2024

Study information

Verified date March 2024
Source Mario Negri Institute for Pharmacological Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in newly diagnosed, previously untreated epilepsy. Original trials and Cochrane reviews show that seizure remission can be achieved with differing daily doses. In clinical practice, the first maintenance dose varies significantly. In contrast, the risk of adverse treatment effects increases with dosage. There is thus the need to identify the lowest effective dose for treatment start. This background prompted us to undertake a randomized multicenter pragmatic non-inferiority trial comparing standard to low daily doses of AEDs to demonstrate that low doses are at least as effective as standard doses (as indicated by the national formulary) but are better tolerated and are associated with a better quality of life. If proven as effective as the standard dose, a low daily dose of AEDs is a benefit to the patient in terms of tolerability and safety and a source of savings for the National Health System.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 374
Est. completion date August 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older; 2. Newly diagnosed previously untreated epilepsy, defined according to the ILAE definition (Fisher et al, 2014); 3. Having experienced focal seizures, defined according to the ILAE criteria (Commission, 1981); 4. Able to understand and comply with the study requirements and release a written informed consent. Exclusion Criteria: A patient will be excluded if at least one of the following criteria will be met: 1. Age less than 18 years; 2. Having experienced primarily or secondarily generalized tonic and/or clonic seizures, or other (non-focal) seizure types; 3. Previous exposure to AEDs; 4. Requiring low or standard doses on account of individual needs; 5. Inability to understand the aims or modalities of the study; 6. Current pregnancy or planning to become pregnant during the study period (e.g. who are not post-menopausal, surgically sterile, or using inadequate birth control). A postmenopausal state is defined as no menses for 12 months without an alternative medical cause; 7. Previous treatment with an antiepileptic drug; 8. Men unable to practice contraception for the duration of the treatment. 9. Poor compliance with assigned treatments; 10. Refusal to release written informed consent; 11. The study investigators will receive the summary of product characteristics (SPC) available for each study drug. Patients cannot be enrolled in the study if the contraindications/warnings described in the SPC are met.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Low dose carbamazepine
Carbamazepine, 300 mg/die
Standard dose carbamazepine
Carbamazepine 600 mg/die
Low dose levetiracetam
Levetiracetam 500 mg/die
Standard dose levetiracetam
Levetiracetam 1000 mg/die
Low dose valproate
Valproate 300 mg/die
Standard dose valproate
Valproate 600 mg/die
Low dose zonisamide
Zonisamide 150 mg/die
Standard dose zonisamide
Zonisamide 300 mg/die
Low dose oxcarbazepine
Oxcarbazepine 600 mg/die
Standard dose oxcarbazepine
Oxcarbazepine 1200 mg/die
Low dose topiramate
Topiramate 100 mg/die
Standard dose topiramate
Topiramate 200 mg/die
Low dose lamotrigine
Lamotrigine 100 mg/die
Standard dose lamotrigine
Lamotrigine 200 mg/die
Low dose gabapentin
Gabapentin 450 mg/die
Standard dose gabapentin
Gabapentin 900 mg/die

Locations

Country Name City State
Italy ASST Monza Ospedale San Gerardo Monza

Sponsors (3)

Lead Sponsor Collaborator
Mario Negri Institute for Pharmacological Research Azienda Ospedaliera San Gerardo di Monza, Ministry of Health, Italy

Country where clinical trial is conducted

Italy, 

References & Publications (7)

Abimbola S, Martiniuk AL, Hackett ML, Anderson CS. The influence of design and definition on the proportion of general epilepsy cohorts with remission and intractability. Neuroepidemiology. 2011;36(3):204-12. doi: 10.1159/000327497. Epub 2011 May 24. — View Citation

Beghi E, Niero M, Roncolato M. Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure. 2005 Oct;14(7):452-8. doi: 10.1016/j.seizure.2005.07.008. Epub 2005 Aug 10. — View Citation

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. — View Citation

Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002 Apr 23;58(8 Suppl 5):S9-20. doi: 10.1212/wnl.58.8_suppl_5.s9. — View Citation

Maguire M, Marson AG, Ramaratnam S. Epilepsy (partial). BMJ Clin Evid. 2010 Jun 28;2010:1214. — View Citation

Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, Thurman DJ, Hauser WA, Gilliam FG, Hesdorffer DC. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011 Jan 18;76(3):273-9. doi: 10.1212/WNL.0b013e318207b073. — View Citation

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981 Aug;22(4):489-501. doi: 10.1111/j.1528-1157.1981.tb06159.x. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment failure The proportion of patients experiencing a treatment failure motivated by the need to change the assigned dose or the assigned drug for seizure relapse during the follow-up. 12 months
Secondary Drug-related adverse events the proportion of patients experiencing a treatment failure motivated by intolerable drug-related adverse events during the follow-up; 12 months
Secondary Quality of life in epilepsy scale 31 items(QOLIE-31), italian version QOLIE-31 total score at baseline and last visit. Maximum total score is 100 (best quality of life possible) and the minimum is 0 (worst quality of life possible). 12 months
Secondary Patients health care's satisfaction (PSQ-18) scale, 18 items The score of the seven PSQ-18 subscales (general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, accessibility and convenience) at baseline and last visit. Possible scores of each subscale range from 1 (worst satisfaction) to 5 (better satisfaction). There is no total score for this scale. 12 months
Secondary Health care resources utilization. The mean daily patient's cost of health care resources consumed for the management of epilepsy during the first 12 months of the study. 12 months
See also
  Status Clinical Trial Phase
Terminated NCT00524030 - Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures Phase 3
Completed NCT00143143 - Pregabalin Open-Label Extension Trial in Patients With Partial Seizures Phase 3
Completed NCT00771927 - Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures N/A
Completed NCT00236873 - A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. Phase 2
Completed NCT01745952 - Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS) N/A
Completed NCT00772603 - Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures Phase 3
Completed NCT00280696 - A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures Phase 3
Completed NCT00643136 - A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures Phase 3
Completed NCT00230698 - A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure Phase 3
Completed NCT00072813 - MRI in Autosomal Dominant Partial Epilepsy With Auditory Features N/A
Enrolling by invitation NCT04309812 - Transcranial Direct Current to Treat Epilepsy at Home Early Phase 1
Withdrawn NCT00422110 - A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures Phase 2/Phase 3
Completed NCT00620555 - A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures Phase 3
Completed NCT00448916 - Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures Phase 3
Completed NCT00210522 - An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy Phase 2
Completed NCT00236886 - Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients Phase 3
Completed NCT00236860 - A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures Phase 2
Completed NCT01098162 - Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug N/A
Completed NCT05273398 - Effects of Diazepam on RNS Detections Phase 4
Completed NCT00918047 - Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients Phase 1